Share Prices & Company Research

Market News

22 Feb 2021 | 08:04

AstraZeneca withdraws Imfinzi US indication for advanced bladder cancer

(Sharecast News) - Drugmaker AstraZeneca announced the voluntary withdrawal of its Imfinzi indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer on Monday. AstraZeneca, which stated its decision was made in consultation with the Food and Drug Administration, stated that Imfinzi was granted accelerated approval in the US based on promising tumour response rates and duration of response data from Study 1108, a Phase I/II trial that evaluated the safety and efficacy of the drug in advanced solid tumours.

However, the FTSE 100-listed group noted that continued approval was contingent on results from its DANUBE Phase III trial in the first-line metastatic bladder cancer setting, which failed to meet its primary endpoints in 2020.

Despite the setback in the US, AstraZeneca pointed out that the withdrawal did not impact the drug's indication outside the States.

As of 0820 GMT, AstraZeneca shares were up 0.39% at 7,254.0p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.